Before and After the Introduction of Antiretroviral Therapy

were not statistically different. Fifty-two subjects (91%), regardless of treatment group, had a nadir below 200/ µL. Of the subjects undergoing ART, 28 (82%) developed EF within 6 months of initiating ART; their averageCD4cellcountincreasewas108/µL.Ofthe23subjects receiving protease inhibitor/nonnucleoside reverse transcriptase inhibitor–containing ART regimens, 17 (74%) were diagnosed as having EF within 3 months, with 4 additional subjects diagnosed as having EF within 6 months (a total of 21 [91%] of the 23 subjects). This is not significantly different from the 7 (64%) of 11 subjects diagnosed as having EF at 3 and 6 months of starting ART without protease inhibitors/nonnucleoside reversetranscriptaseinhibitors(P=.07)(oddsratio,0.18; 95% confidence interval, 0.01-1.54).